FC
PTCT icon

Financial Consulate’s PTC Therapeutics PTCT Stock Holding History

Financial Consulate’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341 Hold
5
– – ﹤0.01% 1325
2025
Q4 		$380 Hold
5
– – ﹤0.01% 1249
2025
Q3 		$307 Buy
+5
New +$260 ﹤0.01% 1111

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Financial Consulate's PTCT Position: Q1 2026 in Review

Financial Consulate held its PTC Therapeutics (PTCT) position steady in Q1 2026 at 5 shares worth $341. The position accounts for ﹤0.01% of the portfolio, ranked #1325.

Financial Consulate first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $380 in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Financial Consulate held 5 shares of PTC Therapeutics worth $341 as of Q1 2026.
  • Financial Consulate left its PTC Therapeutics share count unchanged in Q1 2026.
  • PTC Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #1325 holding.
  • Financial Consulate first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Financial Consulate's PTC Therapeutics position peaked at $380 in Q4 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.